血紅素病市場－全球產業規模、佔有率、趨勢、機會及預測，依類型（地中海型貧血、鐮狀細胞疾病、其他血紅素變異體）、診斷、治療、地區和競爭格局分類，2020-2030年預測

2024年全球血紅素病市場規模為84.4億美元，預計2030年將以12.7%的複合年成長率成長至172.9億美元。血紅蛋白疾病是一組遺傳性血液疾病，其特徵是血紅蛋白分子的結構或生成異常，而血紅蛋白分子對於紅血球內的氧氣運輸至關重要。全球血紅蛋白疾病市場成長的主要促進因素是這些遺傳性疾病在全球的盛行率不斷上升，以及診斷技術和治療方法的顯著進步。

主要市場促進因素

主要市場挑戰

主要市場趨勢

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球血紅素疾病市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依類型（地中海型貧血、鐮狀細胞疾病、其他血紅素（Hb）變異體）
  • 依診斷（地中海型貧血{血液檢查、基因檢測、產前基因檢測、胚胎植入前遺傳學診斷、電泳、其他}、鐮狀細胞疾病{血液檢查、基因檢測、產前基因檢測、電泳、其他}、其他{血液檢查、基因檢測、產前基因檢測、電泳、其他}）
  • 依治療方法分類（地中海型貧血{輸血、鐵螯合療法、骨髓移植、其他}、鐮狀細胞疾病{輸血、羥基脲、骨髓移植、其他}、其他{輸血、羥基脲、鐵螯合療法、骨髓移植、其他}）
  • 按地區
  • 按公司（2024 年）
• 市場地圖

第6章：北美血紅素疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲血紅素病市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區血紅素疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲血紅素疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲血紅素疾病市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章：市場動態

• 促進要素
• 挑戰

第12章：市場趨勢與發展

• 併購（如有）
• 產品發布（如有）
• 最新進展

第13章：全球血紅素疾病市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商議價能力
• 顧客的力量
• 替代產品的威脅

第15章：競爭格局

• Sangamo Therapeutics, Inc.
• Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• bluebird bio, Inc.
• Emmaus Medical, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Sanofi SA (Bioverativ Inc.)
• Gamida Cell Ltd.
• Celgene Corporation
• Abbott Laboratories, Inc.

第16章：策略建議

第17章調查會社について,免責事項

The Global Hemoglobinopathies Market , valued at USD 8.44 Billion in 2024, is projected to experience a CAGR of 12.7% to reach USD 17.29 Billion by 2030. Hemoglobinopathies represent a group of inherited blood disorders characterized by abnormalities in the structure or production of the hemoglobin molecule, crucial for oxygen transport within red blood cells. The global market for these conditions is primarily driven by the increasing worldwide prevalence of these genetic disorders and significant advancements in diagnostic technologies and therapeutic interventions.

Key Market Drivers

The global hemoglobinopathies market is significantly influenced by the increasing worldwide prevalence of these genetic disorders and the continuous emergence of novel and gene-based therapies. The rising prevalence contributes directly to a larger patient pool requiring diagnosis, treatment, and ongoing care, thereby expanding the overall market demand. According to The Lancet Haematology, in June 2023, the number of people living with sickle cell disease globally increased by 41.4% from 2000 to 7.74 million in 2021, highlighting a substantial and growing patient population. This demographic shift necessitates enhanced healthcare resources and drives investments in therapeutic solutions.

Key Market Challenges

The substantial cost associated with novel, advanced therapies, particularly gene therapies and bone marrow transplantation, represents a significant impediment to the global hemoglobinopathies market's expansion. These treatments, while offering the potential for transformative outcomes, are often accompanied by prohibitively high price tags. For instance, according to the Sickle Cell Disease Association of America, in December 2023, the list price for Casgevy, a gene therapy for sickle cell disease, was estimated at $2.2 million, while Lyfgenia, another gene therapy for the same condition, was estimated at $3.1 million.

Key Market Trends

Artificial intelligence is a significant trend, enhancing diagnostic precision and efficiency for hemoglobinopathies by streamlining complex data analysis. This technology leverages genetic information and medical records for quicker and more accurate disorder identification. While its potential is substantial, challenges remain; according to the National Institutes of Health, in August 2024, the best-performing AI models achieved only 21 percent accurate diagnoses from patient-written genetic condition descriptions, emphasizing areas for refinement. Despite these, AI proves impactful in personalized monitoring.

Key Market Players

• Sangamo Therapeutics, Inc.
• Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• bluebird bio, Inc.
• Emmaus Medical, Inc.
• Novartis AG
• Prolong Pharmaceuticals, LLC
• Sanofi S.A. (Bioverativ Inc.)
• Gamida Cell Ltd.
• Celgene Corporation
• Abbott Laboratories, Inc.

Report Scope:

In this report, the Global Hemoglobinopathies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemoglobinopathies Market , By Type:

• Thalassemia
• Sickle Cell Disease
• Other Hemoglobin (Hb) Variants

Hemoglobinopathies Market , By Diagnosis:

• Thalassemia {Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others}
• Sickle Cell Disease {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}
• Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}

Hemoglobinopathies Market , By Therapy:

• Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}
• Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}
• Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others}

Hemoglobinopathies Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Hemoglobinopathies Market .

Available Customizations:

Global Hemoglobinopathies Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Hemoglobinopathies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants)
  • 5.2.2. By Diagnosis (Thalassemia {Blood Test, Genetic Test, Prenatal Genetic Test, Pre-implantation Genetic Diagnosis, Electrophoresis, Others}, Sickle Cell Disease {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others}, Other {Blood Test, Genetic Test, Prenatal Genetic Test, Electrophoresis, Others})
  • 5.2.3. By Therapy (Thalassemia {Blood Transfusion, Iron Chelation Therapy, Bone Marrow Transplant, Others}, Sickle Cell Disease {Blood Transfusion, Hydroxyurea, Bone Marrow Transplant, Others}, Other {Blood Transfusion, Hydroxyurea, Iron Chelation Therapy, Bone Marrow Transplant, Others})
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. North America Hemoglobinopathies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Diagnosis
  • 6.2.3. By Therapy
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Hemoglobinopathies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Diagnosis
      • 6.3.1.2.3. By Therapy
  • 6.3.2. Canada Hemoglobinopathies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Diagnosis
      • 6.3.2.2.3. By Therapy
  • 6.3.3. Mexico Hemoglobinopathies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Diagnosis
      • 6.3.3.2.3. By Therapy

7. Europe Hemoglobinopathies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Diagnosis
  • 7.2.3. By Therapy
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Hemoglobinopathies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Diagnosis
      • 7.3.1.2.3. By Therapy
  • 7.3.2. France Hemoglobinopathies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Diagnosis
      • 7.3.2.2.3. By Therapy
  • 7.3.3. United Kingdom Hemoglobinopathies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Diagnosis
      • 7.3.3.2.3. By Therapy
  • 7.3.4. Italy Hemoglobinopathies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Diagnosis
      • 7.3.4.2.3. By Therapy
  • 7.3.5. Spain Hemoglobinopathies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Diagnosis
      • 7.3.5.2.3. By Therapy

8. Asia Pacific Hemoglobinopathies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Diagnosis
  • 8.2.3. By Therapy
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Hemoglobinopathies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Diagnosis
      • 8.3.1.2.3. By Therapy
  • 8.3.2. India Hemoglobinopathies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Diagnosis
      • 8.3.2.2.3. By Therapy
  • 8.3.3. Japan Hemoglobinopathies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Diagnosis
      • 8.3.3.2.3. By Therapy
  • 8.3.4. South Korea Hemoglobinopathies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Diagnosis
      • 8.3.4.2.3. By Therapy
  • 8.3.5. Australia Hemoglobinopathies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Diagnosis
      • 8.3.5.2.3. By Therapy

9. Middle East & Africa Hemoglobinopathies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Diagnosis
  • 9.2.3. By Therapy
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Hemoglobinopathies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Diagnosis
      • 9.3.1.2.3. By Therapy
  • 9.3.2. UAE Hemoglobinopathies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Diagnosis
      • 9.3.2.2.3. By Therapy
  • 9.3.3. South Africa Hemoglobinopathies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Diagnosis
      • 9.3.3.2.3. By Therapy

10. South America Hemoglobinopathies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Diagnosis
  • 10.2.3. By Therapy
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Hemoglobinopathies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Diagnosis
      • 10.3.1.2.3. By Therapy
  • 10.3.2. Colombia Hemoglobinopathies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Diagnosis
      • 10.3.2.2.3. By Therapy
  • 10.3.3. Argentina Hemoglobinopathies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Diagnosis
      • 10.3.3.2.3. By Therapy

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Hemoglobinopathies Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Sangamo Therapeutics, Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Pfizer, Inc. (Global Blood Therapeutics, Inc.)
• 15.3. bluebird bio, Inc.
• 15.4. Emmaus Medical, Inc.
• 15.5. Novartis AG
• 15.6. Prolong Pharmaceuticals, LLC
• 15.7. Sanofi S.A. (Bioverativ Inc.)
• 15.8. Gamida Cell Ltd.
• 15.9. Celgene Corporation
• 15.10. Abbott Laboratories, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer